

1 **Identification of Novel and Differentially Expressed MicroRNAs in Goat Enzootic Nasal**

2 **Adenocarcinoma**

3 Wang Bin<sup>1</sup>, Ye Ni<sup>1#</sup>, Cao San-jie<sup>1</sup>, Wen Xin-tian<sup>1</sup>, Huang Yong<sup>1</sup>, Yan Qi-gui<sup>1&\*</sup>

4 Wang Bin [binwang2@163.com](mailto:binwang2@163.com) Sichuan Agricultural University, Xin kang Road 46 Ya'an,  
5 Sichuan 625000, P. R. China

6 Ye Ni [yenicq@163.com](mailto:yenicq@163.com) Sichuan Agricultural University, Xin kang Road 46 Ya'an, Sichuan  
7 625000, P. R. China

8 Cao San-jie [csanjie@sicau.edu.cn](mailto:csanjie@sicau.edu.cn) Sichuan Agricultural University, Xin kang Road 46  
9 Ya'an, Sichuan 625000, P. R. China  
10

11 Wen Xin-tian [xintian@sicau.edu.cn](mailto:xintian@sicau.edu.cn) Sichuan Agricultural University, Xin kang Road 46  
12 Ya'an, Sichuan 625000, P. R. China

13 Huang Yong [hyong601@163.com](mailto:hyong601@163.com) Sichuan Agricultural University, Xin kang Road 46  
14 Ya'an, Sichuan 625000, P. R. China

15 Yan qi-gui [yanqigui@126.com](mailto:yanqigui@126.com) Sichuan Agricultural University, Xin kang Road 46 Ya'an,  
16 Sichuan 625000, P. R. China

17

18 <sup>1</sup>College of Veterinary Medicine, Sichuan Agricultural University, Yaan, Sichuan 625000, P. R.  
19 China

20 # Ye Ni as the joint first author

21 &Yan Qi-gui as the corresponding author

22 \* To whom correspondence may be addressed: College of Veterinary Medicine, Sichuan  
23 Agricultural University, Yaan, Sichuan. Tel: +0835-28-824-23; Tel: +0835-28-824-23; E-mail:

24 yanqigui@126.com.

25

26 Running title: Differentially expressed miRNAs in goat ENA

27

28 **Abstract**

29 Enzoitic nasal adenocarcinoma (ENA), an epithelial tumor induced in goats and sheep by  
30 enzoitic nasal tumor virus (ENTV), is a chronic, progressive, contact transmitted disease.  
31 This study aimed to identify novel and differentially expressed miRNAs in the tumor and  
32 para-carcinoma nasal tissues of Nanjiang yellow goats with ENA. Small RNA Illumina  
33 high-throughput sequencing was used to construct a goat nasal miRNA library.  
34 406 known miRNAs and 29 novel miRNAs were identified. A total of 116 miRNAs were  
35 significantly differentially expressed in para-carcinoma nasal tissues and ENA; Target gene  
36 prediction and functional analysis revealed that 6176 non-redundancy target genes, 1792  
37 significant GO and 97 significant KEGG pathway for 121 miRNAs were predicted.

38 **Keywords:** MicroRNA; Enzoitic Nasal Adenocarcinoma; Illumina High-throughput  
39 Sequencing; Gene ontology; KEGG pathway

40 MicroRNAs (miRNAs) are endogenous, 21-24 nucleotide-long, non-coding RNAs that  
41 regulate gene expression in eukaryotes; however, some viruses also express miRNAs in host  
42 cells (Bartel 2004; Pfeffer et al. 2004; Filipowicz et al. 2005). MiRNAs are complementary to  
43 specific sequence motifs in the 3` untranslated regions (UTRs) of their target mRNAs and  
44 negatively regulate gene expression at the post-transcriptional level by inhibiting translation  
45 or promoting mRNA degradation, based on the degree of complementary base pairing  
46 between the miRNA and mRNA. MiRNAs regulate approximately 30% of genes in higher  
47 eukaryotic cells, including genes involved in development, metabolism, apoptosis,  
48 proliferation and viral defense(Kincaid and Sullivan 2012; Dong et al. 2013; Zhang et al.  
49 2013; Wang and Kaufman 2014; Zhang et al. 2014; Bandiera et al. 2015; Lin et al. 2015). The  
50 earliest evidence for an association between miRNAs and cancer came from the study of  
51 chronic lymphocytic leukemia (CLL) (Calin et al. 2002). To date, more than 50% of miRNAs  
52 have been shown to be encoded in chromosome fragile sites that are often absent, amplified  
53 or rearranged in malignant tumor cells leading to dysregulated expression of miRNAs, and  
54 numerous miRNAs have been shown to play important roles in tumorigenesis (Calin et al.  
55 2004). MiRNAs can act in a similar manner to oncogenes or tumor suppressor genes and have  
56 emerged as a novel type of regulatory factor in the epigenetic modification of gene expression.  
57 According to predictions in vertebrates, a single miRNA can regulate more than 400 target  
58 genes, forming complicated regulatory networks(Lewis et al. 2003; Landgraf et al. 2007;  
59 Ruby et al. 2007; Bartel 2009). Therefore, miRNAs have become a focus of cancer research  
60 in order to identify novel molecular methods for the diagnosis, prognostication and treatment  
61 of human cancer. Now researchers can directly obtain miRNA sequences and discover novel

62 miRNAs through utilize Illumina high-throughput sequencing technology(Ye et al. 2012).

63       Enzootic nasal adenocarcinoma (ENA) is an epithelial tumor caused by enzootic nasal  
64 tumor virus (ENTV), and is a chronic, progressive, contact transmitted disease(Heras et al.  
65 2003). With the exception of Australia and New Zealand, this disease has spread throughout  
66 goats or sheep almost worldwide (Kawasako et al. 2005). ENA originates from the ethmoid  
67 area of the nasal cavity either unilaterally or bilaterally, and the tumors are soft, whitish or  
68 pinkish-red in color and can partially or completely obscure the nasal cavity(Walsh et al.  
69 2010). Metastases to the regional lymph nodes, brain or other organs does not occur(Yi et al.  
70 2010). So far, there are no effective methods for early diagnosis of ENA and the goats or  
71 sheep can only be culled after symptoms appear. More seriously, as it is difficult to  
72 distinguish between animals with a latent infection and healthy animals, the virus spreads  
73 within herds, and can infect a large number of goats or sheep and threaten the entire  
74 population.

75       There are currently 2581 human miRNAs in the miRbase (v21) database; however, there is  
76 no public miRNA library of *Capra hircus* nasal tissues and there have been no reports of  
77 miRNAs in ENA. To further complicate matters, attempts to establish a system of cultivating  
78 ENTV *in vitro* have failed, which presents a significant obstacle to investigating the  
79 immunological characteristics of ENTV and the mechanisms by which it promotes  
80 tumorigenesis (De las Heras et al. 1995). Therefore, taking advantage of knowledge of the  
81 roles of miRNAs in human cancer to research the miRNAs involved in ENA may not only  
82 avoid the problem of cultivating ENTV *in vitro*, but also shifts the focus to the cells targeted  
83 by ENTV - goat or sheep nasal epithelial cells - and may provide an alternative method for

84 investigating the tumorigenic effects of ENTV.

85 Using Illumina high-throughput sequencing technology to detect miRNAs expressed in the  
86 tumor and para-carcinoma nasal tissues of Nanjiang yellow goats with ENA, we constructed  
87 the first goat nasal tissue miRNA library. Furthermore, the target genes of the differentially  
88 expressed miRNAs in ENA were predicted and their corresponding biological functions were  
89 analyzed. This research may help to identify novel biomarkers for ENA, lays a foundation for  
90 investigating the mechanism by which ENTV promotes tumorigenesis, and provides further  
91 information on the role of miRNAs in cancer. Furthermore, as the sequences and roles of  
92 miRNAs are well conserved, the findings of this study may also be relevant to human cancers  
93 such as nasopharyngeal carcinoma.

## 94 **RESULTS**

### 95 ***Capra hircus* nasal tissue miRNA library**

96 High-throughput sequencing generated hundreds of millions of reads for each tissue. The  
97 raw data (tag sequences and counts) have been submitted to Gene Expression Omnibus (GEO)  
98 under series GSE65305. To estimate sequencing quality, the quality scores were analyzed  
99 across all bases (Fig. 7). The lowest quality score was  $\geq 30$ ; therefore, the error rate was lower  
100 than 0.1%. Reads including adaptor sequences, low quality sequences and sequences of  
101 unqualified length were removed, and the remaining clean reads were aligned with the *Capra*  
102 *hircus* genome in NCBI using Bowtie software to analyze the genomic distribution and  
103 expression of small RNAs. The vast majority of clean reads (at least 84.75%) and unique  
104 reads (at least 57.56%) mapped to the *Capra hircus* genome (Table 1).

105 Unique reads were blasted against the Rfam, RepBase, EST and miRBase databases, in the

106 order of known miRNAs > rRNAs > tRNAs > snRNAs > snoRNAs > repeat sequences,  
107 which enabled each small RNA obtain a unique annotation. To exclude other RNAs, such as  
108 tRNAs, rRNAs, snRNAs and snoRNAs, the remaining sequences were mapped to Denovo  
109 prediction data sets and the *Capra hircus* genome to identify novel miRNAs. Using miRDeep  
110 prediction (Friedländer et al. 2008) and RNAfold (Hofacker et al. 1994) software to analyze  
111 secondary structure. A total of 435 sequences (29 novel miRNAs) were included in the  
112 miRNA library. Table S1 displays the sequencing generated codes and corresponding *Capra*  
113 *hircus* miRNAs or novel miRNA\_id. As research into miRNAs in human cancer is  
114 widespread, we blasted all goat miRNAs against the human miRNAs in miRBase v21 to  
115 further understand their function. A total of 615 of the goat miRNAs had analogues in the  
116 human miRNA datasets (Table S2).

### 117 **Identification of differentially expressed miRNAs in ENA**

118 A total of 435 miRNAs were identified in the ENA and para-carcinoma tissues. The table  
119 S3 lists the expression of all miRNAs. The expression of 116 miRNAs was significantly  
120 different in para-carcinoma tissues and ENA, of which 54 were downregulated and 60 were  
121 upregulated in ENA. In addition, 2 miRNAs were only expressed in the para-carcinoma  
122 tissues (Table S4). The majority of the fold change- $\log^2$  values ranged from 1 to 5.42;  
123 chi-miR-133a-3p had the highest fold-change- $\log^2$  of at least 5.4-fold, and 65 miRNAs had  
124 fold-change- $\log^2$  values of at least two-fold. Figure 8 indicates the differences in expression  
125 of all 435 miRNAs between ENA and the para-carcinoma tissues.

### 126 **Functional analysis of differentially expressed target genes regulated by differentially** 127 **expressed miRNAs**

128           The Miranda algorithm indicated thousands of potential target genes for the 435 miRNAs.  
129   According to the total scores and predicted energies, the 6176 non-redundancy target genes of  
130   these 121 miRNA(116 significant expression miRNAs and 5 star miRNAs ) were selected,  
131   reflecting 15222 corresponding relationships between the differentially expressed miRNAs  
132   and their target genes. Table S5 shows the total stores, total energy, and protein-id and  
133   genomic location of predicted target genes.

134           The expression of these candidate target genes was assessed in the high throughput  
135   sequencing data obtained from the same ENA and para-cancerous tissue samples (data not  
136   shown; this data will be described in another article). A total of 175 mRNAs that were  
137   significantly differently expressed in ENA were selected for this analysis. Table S6 lists the  
138   differentially expressed miRNAs and their corresponding differentially expressed target genes.  
139   Table S7 summarizes the degree of regulation between the differentially expressed miRNAs  
140   and their differentially expressed target mRNAs.

#### 141   **MiRNA-gene ontology network analysis of miRNA target genes**

142           Functional analysis was conducted on the mRNAs predicted as targets of the 435  
143   differentially expressed miRNAs. A total of 9777 GO enrichments were identified, of which  
144   1792 GO categories were significant ( $P \leq 0.05$ ).The mRNA sequencing identified a total of  
145   90 target genes corresponding to miRNAs with significantly decreased expression and 84  
146   target genes corresponding to miRNA with significantly increased expression in tumor group.  
147   472 significant GO enrichments exist in significant expression miRNA-mRNA network(Table  
148   S8). The target genes of the differentially expressed miRNAs were mainly involved in cell  
149   differentiation, MAP kinase activity, cell adhesion and angiogenesis; each of these pathways



150 may be implicated in the tumorigenic effect of ENTV. Figure 9 presents the ten most-enriched  
151 GO categories for the differentially expressed target genes of the differentially expressed  
152 miRNAs in ENA.

### 153 **Analysis of signaling pathways regulated by the miRNA target genes**

154 Signal transduction analysis was conducted on the mRNAs predicted as targets of the  
155 435 differentially expressed miRNAs, and 267 KEGG enrichments were identified of which  
156 97 were significant ( $P \leq 0.05$ ). The target genes of the differentially expressed miRNAs  
157 participate in pathways related to the signal transduction, specific types of cancer and immune  
158 system. Among significantly differently expressed miRNA, miRNA with increased expression  
159 in tumor group were involved in 83 significant signal transduction pathways (Table S9) ,  
160 miRNA with reduced expression in tumor group were involved in 89 significant signal  
161 transduction pathways (Table S10). Figure 10 illustrates the ten most-enriched KEGG  
162 pathways for the differentially expressed target genes of the differentially expressed miRNAs  
163 in ENA.

### 164 **Quantitative RT-PCR validation of differentially expressed miRNAs**

165 We selected 9 of the key miRNAs that were significantly differently expressed in ENA  
166 including five miRNAs that featured in both the GO and KEGG pathway analyses and two  
167 novel miRNAs (NW\_005102245.1\_1433, NC\_022308.1\_285). The main functions of target  
168 genes regulated by these miRNAs are involved in cancer pathogenesis, virus infection, cell  
169 apoptosis and proliferation. As shown in Figure 11, qRT-PCR confirmed the expression of the  
170 nine miRNAs between ENA and the para-cancerous tissues with an increased sample size.  
171 The expression trend of eight miRNAs is in accord with Illumina High-Throughput

172 Sequencing, one miRNA(chi-miR-218) both in sequencing and qPCR verification have  
173 shown a down-expression in tumor group, but the down-expression multiple is different.

#### 174 **Discussion**

175 ENTV, a betaretrovirus that infects sheep (ENTV-1) and goats (ENTV-2), is associated with  
176 neoplastic transformation of ethmoid turbinate epithelial cells and leads to ENA. The clinical  
177 symptoms of goats are a loss of appetite, extreme weight loss, dyspnea, rhinorrhea, and  
178 unilateral or bilateral nasal puffiness. The incidence of ENTV infection ranges from 5% to  
179 15%, and once the clinical symptoms of ENA appear, almost all cases are fatal (Rings and  
180 Rojko 1985; De las Heras et al. 1991; Vitellozzi et al. 1993). High-throughput sequencing  
181 technology is gradually being used in animal and has provided some knowledge of goat  
182 miRNAs. Ji et al. (Ji et al. 2012) discovered 290 known miRNAs and 38 novel miRNAs in  
183 dairy goat mammary gland tissue and reported that miRNA-mediated regulation of gene  
184 expression occurs during early lactation. Hao et al. (Yu and Jun 2014)found that the  
185 expression of 64 miRNAs was reduced in the skin of a 70-day fetus relative to a lamb born at  
186 2 weeks, with the expression of ten miRNAs decreasing more than 5-fold, which implies that  
187 miRNAs play an important role in maintaining normal skin function.

188 Cancer is a leading cause of morbidity and death in humans. Significant research has been  
189 conducted on miRNAs in human cancer, and miRNAs have been demonstrated to be directly  
190 involved in human nasopharyngeal carcinoma (NPC). For example, miR-29c, the miR-34  
191 family, miR-143, miR-145 and miR-9 are downregulated in NPC, leading to increased  
192 expression of their target genes which influence the function and synthesis of extracellular  
193 matrix proteins, which in turn affects tumor invasion and metastasis, and activates the

194 TGF-Wnt, IP3 and VEGF signaling pathways (Sengupta et al. 2008; Chen et al. 2009). In  
195 contrast, miR-200, the miR-17-92 cluster and miR-155 are upregulated in NPC, and miR-200  
196 inhibits the migration and invasion of NPC cells by inhibiting the expression of *ZEB2* (zinc  
197 finger E-box binding homeobox 2) and *CTNNB1*(catenin- $\beta$ -like 1) (Xia et al. 2010). By  
198 blasting the 435 miRNAs identified using high-throughput sequencing in this study against  
199 the human miRNA datasets in miRBase, we found that hsa-miR-9, hsa-miR-34 and  
200 hsa-miR-143 are significantly downregulated and hsa-miR-200 is significantly upregulated in  
201 ENA. GO and KEGG pathway analysis revealed these miRNAs are involved in intracellular  
202 signal transduction, the MAPK cascade and cell morphogenesis, among other processes.

203 Our study found according to the percentage, the top five signaling pathways are MAPK  
204 signaling pathway, Pathways in cancer, PI3K-Akt signaling pathway, Ras signaling pathway  
205 and Viral carcinogenesis. Kano et al. (Kano et al. 2010) and Chiyomaru et al. (Chiyomaru et  
206 al. 2010) found that miR-133a was significantly inhibited human esophageal squamous cell  
207 cancer and the invasion of bladder cancer cell. Iorio (Iorio et al. 2005) found that expression  
208 of miR-133a significantly reduced during the progression of breast cancer. Our results also  
209 reveal the expression of miR-133a-3p was at least 5-fold lower in ENA compared to  
210 para-carcinoma nasal tissues. These results suggest that miR-133a-3p may regulate the  
211 expression of oncogenes and inhibit tumorigenesis. KEGG analysis displayed that the target  
212 genes of miR-133a-3p are involved in tumor biology at multiple nodes, such as regulation of  
213 cell differentiation, apoptosis, signal transduction and cell adhesion, invasion and migration.  
214 In esophageal squamous cell carcinoma and bladder cancer, miR-133a targets fascin  
215 actin-bundling protein 1(*FSCN1*) to regulate cancer cell invasion, migration and proliferation

216 (Iorio et al. 2005; Kano et al. 2010). However, in this study we identified that  
217 serine/threonine-protein kinase B-raf (*BRAF*) as chi- miR-133a-3p,  
218 chi-miR-145-5p,chi-miR-146a/200a and two novel miRNA(NC-022308.1-260 ,  
219 NC-022294.1-874) target gene which acts upstream regulatory factor in  
220 RAS-RAF-MEK-ERK. Sustained activation of *BRAF* will lead to cell deterioration and  
221 excessive proliferation(Ji et al. 2007). In addition, the miR-133a-3p target genes:*MDS1* and  
222 *EVI1* complex (*MECOM*) may also play a significant role in pathways related to cancer. In  
223 chronic myeloid leukemia (*CML*), expression of the oncogene *MECOM* correlates with  
224 progression. The tyrosine kinase catalytic activity of the oncoprotein BCL-ABL1 regulates  
225 *MECOM* expression, and conversely *MECOM* partially mediates BCR-ABL1 activity (Roy et  
226 al. 2012); BCR-ABL1 activates the PI3K, MAPK and JAK-STAT signal transduction  
227 pathways (Pendergast et al. 1993; Carlesso et al. 1996; Skorski et al. 1997) to promote  
228 abnormal proliferation, differentiation, transformation and survival in myeloid cells (Smith et  
229 al. 2003). However, forkhead box O (*FoxO*) as the intersection of PI3K and RAS signaling  
230 pathway can inhibit cell proliferation and induce cell cycle stop. The activation of the PI3K  
231 signaling pathway inhibits the activity of the FoxO transcription factor(Schmidt et al. 2002;  
232 Martínez-Gac et al. 2004),which increase the chances of tumor formation. Further study is  
233 required to determine if *MECOM* and BCR-ABL1 play a role in the pathogenesis of ENA.

234 miR-148a is an oncogene that is upregulated in hepatocellular carcinoma cells (*HCC*) and  
235 enhances cell proliferation, migration, invasion and stimulates the epithelial to mesenchymal  
236 transition (*EMT*) by targeting tumor suppressor gene: phosphatase and tensin homolog  
237 (*PTEN*)(Yuan et al. 2012). However, *PTEN* was not identified as a target of miR-148a in this

238 study. Its predicted targets were the transforming growth factor  $\beta$  receptor associated protein  
239 1( *TGF $\beta$ RAP1*) which can specifically combine with the receptor of transforming growth  
240 factor  $\beta$ (*TGF $\beta$* ),and then help to realize the biological function of TGF $\beta$ (Chen et al.  
241 1995).TGF $\beta$  can inhibit cells growth in malignant tumor such as head and neck squamous  
242 cancer, colon cancer, breast cancer(Arteaga et al. 1990; Wu et al. 1992; Briskin et al.  
243 1995).The present studies have pointed out that the expression of TGF $\beta$  in nasopharyngeal  
244 phosphorus tumor generally weakened or even disappear, but the adjacent epithelium have  
245 stronger expression(Bin et al. 1999). The expression of miR-148a-3p was at least 2.5-fold  
246 higher in ENA compared to para-carcinoma nasal tissues. Influenced by miR-148-3p  
247 expression, *TGF $\beta$ RAP1* will drop, which will affect the signal pathway of TGF $\beta$  and make the  
248 cancer cell reduction or loss of ability to react to TGF $\beta$ , finally, the tumor cells escape from  
249 negative growth regulation of TGF $\beta$ .Although this is our speculation, but we believe there is a  
250 link between them.

## 251 **Conclusions**

252 This study provides a solid basis for further research and highlights a number of miRNAs  
253 and genes that may be involved in the pathogenesis of ENA. This study of miRNAs in ENA  
254 may also provide useful information for basic research into human cancer. In future studies,  
255 we aim to confirm the function of the candidate miRNAs in nasal cells. In addition, we hope  
256 that these studies may provide some clues to help establish a method for cultivating ENTV *in*  
257 *vitro*.

## 258 **Methods**

## 259 **Ethics Statement**

260 This study was carried out in strict accordance with the Guidelines for Experimental  
261 Animals of the Ministry of Science and Technology (revised in 2004; Beijing, China) and was  
262 approved by the Institutional Animal Care and Use Ethics Committee of Sichuan Agricultural  
263 University, NO. SYXK (Chuan) 2014-187.

#### 264 **Animals and tissue samples**

265 Eight goats (3a-4a) infected by ENTV under natural conditions at a farm in Sichuan were  
266 quarantined and transported to Sichuan Agricultural University laboratory animal center, and  
267 grew up the center. After slaughter, tumor and para-carcinoma nasal tissues were collected,  
268 frozen rapidly in liquid nitrogen and stored at -80°C. After pathological analysis, the samples  
269 from three Nanjiang yellow goats whose nasal passages were unilaterally blocked by tumors  
270 were selected for high-throughput sequencing. The nasal tumors in these animals were poorly  
271 differentiated (i.e., at the same state of differentiation) with no tumor cell infiltration in the  
272 matched para-carcinoma tissues.

#### 273 **Preparation of samples for sequencing and qPCR**

274 Samples of cDNA from the tumor tissues (numbers S1, S3, S5) and matched  
275 para-carcinoma tissues (numbers S2, S4, S6) of the three animals described above were  
276 shipped on dry ice to Jing Neng Bio-Technology corporation (Shanghai, China) for  
277 high-throughput sequencing. Briefly, total RNA was extracted from the tissues using RNazol  
278 RT RNA Isolation Reagent (GeneCopoela, Rockville, MD, USA) according to the  
279 manufacturer's protocol. The RNA concentrations were determined using a Smart Specplus  
280 Spectrophotometer (Bio-Rad, Hercules, CA, USA) and the integrity of the total RNA samples  
281 was verified by polyacrylamide gel electrophoresis (PAGE). The All-In-One miRNA

282 qRT-PCR Detection Kit (GeneCopoela) was used to add poly(A) tails to the miRNAs in the  
283 total RNA samples and M-MLV reverse transcriptase was used to synthesize cDNA according  
284 to the manufacturer's instructions. Each reaction mixture contained 5  $\mu$ L of 5x reaction buffer,  
285 1  $\mu$ L RTase Mix, 1  $\mu$ L of 2.5 U/ $\mu$ L PolyA Polymerase, 2  $\mu$ g total RNA and  
286 RNase-/DNase-free H<sub>2</sub>O to 25  $\mu$ L, and was incubated at 37°C for 1 h and then at 85°C for 5  
287 min to inactivate the enzyme.

### 288 **Analysis of sequence data and creation of miRNA library**

289 Single-read 50 bp sequencing was adopted for high-throughput sequencing. Illumina  
290 CASAVA software was used to convert the original data image files into sequence files, and  
291 FastQC statistical software was used to evaluate the quality of the data. Primer, adaptor and  
292 low quality sequences were excluded and 15-40 base sequences meeting the length and  
293 quality requirements were selected as clean reads of reliable quality for further  
294 analysis(Figure 1-6). Total clean reads from each individual sample were aligned with the  
295 *Capra hircus* genome in NCBI ([ftp://ftp.ncbi.nlm.nih.gov/genomes/Capra\\_hircus](ftp://ftp.ncbi.nlm.nih.gov/genomes/Capra_hircus)) using  
296 Bowtie software (Langmead et al. 2009)(<http://bowtie-bio.sourceforge.net/index.shtml>) , and  
297 then blasted against the Rfam (<http://www.sanger.ac.uk/resources/databases/rfam.html>) ,  
298 [RepBase](http://www.girinst.org/replib/) (<http://www.girinst.org/replib/>) , EST (<http://www.ncbi.nlm.nih.gov/nucest/>) and  
299 miRBase (<http://www.mirbase.org/>) databases. Sequence alignment was set to allow only a  
300 single base mismatch, and the results were sorted in the order of known miRNAs > rRNAs >  
301 tRNAs > snRNAs > snoRNAs > repeat, respectively, which enabled each small RNA to  
302 obtain a unique annotation. The remaining sequences were mapped to Denovo prediction data  
303 sets (Bonneau et al. 2006)and the *Capra hircus* genome to exclude known non-miRNA

304 sequences (such as tRNAs, rRNAs, snRNAs and snoRNAs) and identify novel miRNAs.  
305 MiRDeep (Friedländer et al. 2008) and RNAfold (Hofacker et al. 1994) were used to predict  
306 miRNA precursor sequences, star miRNAs and mature miRNAs, and then the energetic  
307 stability, position and read frequencies for each potential miRNA precursor were computed  
308 using miRDeep according to the compatibility of energetic stability, positions, frequencies of  
309 reads. Ultimately, a *Capra hircus* nasal tissue miRNA library was created by combining the  
310 sequencing data from all six samples.

### 311 **Identification of differentially expressed miRNAs in ENA**

312 The sequences in each sample were compared with the miRNA library established in this  
313 study by assessing the numbers of transcripts per million (TPM). TPM was calculated as  
314  $(\text{numbers of each miRNA matched to total reads}) / (\text{number total reads}) \times 10^6$ . TPM is an  
315 indicator of the quantity of miRNA expression per million match paired sequences. The total  
316 numbers of matched pair reads were used in the normalized numerical expression algorithm  
317 to calculate miRNA expression. DESeq (Anders and Huber 2010) software was used to  
318 identify differentially expressed miRNAs between the para-carcinoma tissues (S2, S4, S6)  
319 and ENA (S1, S3, S5) on the basis of a fold-change greater than or equal to two and  $P$ -value  $\leq$   
320 0.05.

### 321 **Prediction and analysis of miRNA target genes**

322 The Miranda algorithm (Enright et al. 2004) was used to predict the target genes of the  
323 miRNAs that were differently expressed in ENA. The threshold parameters for predicting  
324 miRNA target genes were a total score  $\geq 150$ ,  $\Delta G \leq -30$  kcal/mol, and strict 5' seed pairing.  
325 The pathways these candidate target genes are involved in was analyzed by functional



326 annotation utilizing the NCBI, KEGG(<http://www.genome.jp/kegg/>)(Kanehisa et al. 2011)  
327 and GO(<http://geneontology.org/>) (Carbon et al. 2009) databases. Additionally,  
328 high-throughput sequencing allowed the mRNA expression of all of the potential target genes  
329 to be analyzed in the same samples (data not shown); therefore, GO and KEGG analyses  
330 could be conducted on the differentially expressed target genes of the differentially expressed  
331 miRNAs. GO annotation and enrichment analysis was performed for three gene ontologies:  
332 molecular function, cellular components and biological processes. The following formula was  
333 used to calculate the *P*-values:

334

$$P = 1 - \sum_{i=0}^{m-1} \frac{\binom{M}{i} \binom{N-M}{n-i}}{\binom{N}{n}}$$

335

336 where *N* is the number of genes with GO/KEGG annotations; *n* is the number of target gene  
337 candidates in *N*; *M* is the number of genes that annotated to a certain GO term/pathway, and *m*  
338 is the number of target gene candidates in *M*. GO terms and KEGG pathways with a corrected  
339 *P*-value  $\leq 0.5$  were regarded as significantly enriched.

#### 340 **Validation of the expression of key differentially expressed miRNAs**

341 Key miRNAs that were identified in all of the analyses described above were quantified  
342 in ENA and para-carcinoma tissue samples from five goats with ENA whose nasal passages  
343 were unilaterally blocked by tumors. Total RNA was isolated and reverse transcribed as  
344 described above, then the cDNA products were diluted 5-fold with sterile H<sub>2</sub>O and subjected  
345 to quantitative real-time PCR (qPCR) using the All-In-One miRNA qRT-PCR Detection Kit  
346 (GeneCopoela) with U6 snRNA and *GAPDH* as internal references. Each reaction contained

347 10  $\mu$ L of 2x All-in-One qPCR Mix, 2  $\mu$ L All-in-One miRNA qPCR Primer (2  $\mu$ M; prepared  
348 by Life Technologies, Shanghai, China), 2  $\mu$ L Universal Adaptor qPCR Primer (2  $\mu$ M), 2  $\mu$ L  
349 first-strand cDNA and 4  $\mu$ L double distilled water. The cycling conditions were 95°C for 10  
350 min, 40 cycles of 95°C for 10 s, 60°C for 20 s and 72°C for 20 s, followed by melting curve  
351 analysis. Relative quantification was performed using the  $2^{-\Delta\Delta C_t}$  method (Livak and  
352 Schmittgen 2001), and *t*-tests were used to examine the significance of the differences in  
353 expression between the para-carcinoma tissues and ENA.

#### 354 **Availability of data and material**

355 The raw data (tag sequences and counts) have been submitted to Gene Expression Omnibus  
356 (GEO) under series GSE65305.

#### 357 **Abbreviations**

358 **miRNAs**: MicroRNAs **ENA**: Enzootic nasal adenocarcinoma **ENTV**: Enzootic nasal  
359 tumor virus **GO**: Gene Ontology **KEGG**: Kyoto Encyclopedia of Genes and Genomes  
360 **RNA** : ribonucleic acid **UTRs** : untranslated regions **CLL** : chronic lymphocytic leukemia  
361 **PAGE** : polyacrylamide gel electrophoresis **rRNAs** : ribosomal RNAs **tRNAs** : transfer  
362 RNAs **snRNAs** :Small nuclear RNAs **snoRNAs** :Small nucleolar RNAs **TPM** :transcripts  
363 per million **qPCR** : quantitative real-time PCR **GAPDH** : glyceraldehyde-3-phosphate  
364 dehydrogenase **GEO** : Gene Expression Omnibus **NPC** : nasopharyngeal carcinoma

#### 365 **Declarations**

#### 366 **Acknowledgments**

367 The skillful technical assistance of Shanghai Genergy Bio-Corporation is gratefully  
368 acknowledged.

369 **Competing interest**

370 The authors declare no financial conflict of interest

371 **Author Contributions**

372 All authors have read and approved of the submission of the manuscript. Conceived and  
373 designed the experiments: YQG CSJ WXT. Performed the experiments: WB YE. Analyzed  
374 the data: WB YE HY. Contributed reagents/materials/analysis tools: YQG WB YE. Wrote the  
375 paper: WB YN.

376 **References**

- 377 Anders S, Huber W. 2010. Differential expression analysis for sequence count data. *Genome Biol*  
378 **11**(10): R106.
- 379 Arteaga C, Coffey Jr R, Dugger T, McCutchen C, Moses H, Lyons R. 1990. Growth stimulation of human  
380 breast cancer cells with anti-transforming growth factor beta antibodies: evidence for  
381 negative autocrine regulation by transforming growth factor beta. *Cell growth &*  
382 *differentiation: the molecular biology journal of the American Association for Cancer*  
383 *Research* **1**(8): 367-374.
- 384 Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. 2015. miR-122—a key factor and therapeutic target in liver  
385 disease. *Journal of hepatology* **62**(2): 448-457.
- 386 Bartel DP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. *cell* **116**(2): 281-297.
- 387 -. 2009. MicroRNAs: target recognition and regulatory functions. *Cell* **136**(2): 215-233.
- 388 Bin L, Hu C, Zhan F. 1999. [The expression in situ of transforming growth factor beta s, their receptors  
389 and TGF beta-receptor interacting protein-1 in nasopharyngeal carcinoma]. *Zhonghua er bi*  
390 *yan hou ke za zhi* **34**(4): 210-212.
- 391 Bonneau R, Reiss DJ, Shannon P, Facciotti M, Hood L, Baliga NS, Thorsson V. 2006. The Inferelator: an  
392 algorithm for learning parsimonious regulatory networks from systems-biology data sets de  
393 novo. *Genome biology* **7**(5): R36.
- 394 Briskin KB, Fady C, Mickel RA, Wang M, Lichtenstein A. 1995. Inhibition of head and neck squamous  
395 cell carcinoma cell lines by transforming growth factor- $\beta$ . *Otolaryngology-Head and Neck*  
396 *Surgery* **112**(6): 728-734.
- 397 Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K. 2002.  
398 Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in  
399 chronic lymphocytic leukemia. *Proceedings of the National Academy of Sciences* **99**(24):  
400 15524-15529.
- 401 Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F,  
402 Negrini M. 2004. Human microRNA genes are frequently located at fragile sites and genomic  
403 regions involved in cancers. *Proceedings of the National Academy of Sciences of the United*  
404 *States of America* **101**(9): 2999-3004.

- 405 Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S. 2009. AmiGO: online access to ontology  
406 and annotation data. *Bioinformatics* **25**(2): 288-289.
- 407 Carlesso N, Frank DA, Griffin JD. 1996. Tyrosyl phosphorylation and DNA binding activity of signal  
408 transducers and activators of transcription (STAT) proteins in hematopoietic cell lines  
409 transformed by Bcr/Abl. *The Journal of experimental medicine* **183**(3): 811-820.
- 410 Chen H, Chen G, Chen Y, Liao W, Liu C, Chang K, Chang Y, Chen S. 2009. MicroRNA deregulation and  
411 pathway alterations in nasopharyngeal carcinoma. *British journal of cancer* **100**(6):  
412 1002-1011.
- 413 Chen R-H, Miettinen PJ, Maruoka EM, Choy L, Derynck R. 1995. A WD-domain protein that is  
414 associated with and phosphorylated by the type II TGF- $\beta$  receptor.
- 415 Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N,  
416 Nakagawa M. 2010. miR-145 and miR-133a function as tumour suppressors and directly  
417 regulate FSCN1 expression in bladder cancer. *British journal of cancer* **102**(5): 883-891.
- 418 De las Heras M, de Jalon JG, Minguijon E, Gray E, Dewar P, Sharp J. 1995. Experimental transmission of  
419 enzootic intranasal tumors of goats. *Veterinary Pathology Online* **32**(1): 19-23.
- 420 De las Heras M, de Jalon JG, Sharp J. 1991. Pathology of enzootic intranasal tumor in thirty-eight goats.  
421 *Veterinary Pathology Online* **28**(6): 474-481.
- 422 Dong H, Lei J, Ding L, Wen Y, Ju H, Zhang X. 2013. MicroRNA: function, detection, and bioanalysis.  
423 *Chemical reviews* **113**(8): 6207-6233.
- 424 Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS. 2004. MicroRNA targets in Drosophila.  
425 *Genome biology* **5**(1): R1-R1.
- 426 Filipowicz W, Jaskiewicz L, Kolb FA, Pillai RS. 2005. Post-transcriptional gene silencing by siRNAs and  
427 miRNAs. *Current opinion in structural biology* **15**(3): 331-341.
- 428 Friedländer MR, Chen W, Adamidi C, Maaskola J, Einspanier R, Knespel S, Rajewsky N. 2008.  
429 Discovering microRNAs from deep sequencing data using miRDeep. *Nature biotechnology*  
430 **26**(4): 407-415.
- 431 Heras M, Ortin A, Cousens C, Minguijon E, Sharp J. 2003. Enzootic nasal adenocarcinoma of sheep and  
432 goats. *Jaagsiekte Sheep Retrovirus and Lung Cancer*: 201-223.
- 433 Hofacker IL, Fontana W, Stadler PF, Bonhoeffer LS, Tacker M, Schuster P. 1994. Fast folding and  
434 comparison of RNA secondary structures. *Monatshefte für Chemie/Chemical Monthly* **125**(2):  
435 167-188.
- 436 Iorio MV, Ferracin M, Liu C-G, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M,  
437 Campiglio M. 2005. MicroRNA gene expression deregulation in human breast cancer. *Cancer*  
438 *research* **65**(16): 7065-7070.
- 439 Ji H, Wang Z, Perera SA, Li D, Liang M-C, Zaghul S, McNamara K, Chen L, Albert M, Sun Y. 2007.  
440 Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase  
441 pathway in lung cancer mouse models. *Cancer Research* **67**(10): 4933-4939.
- 442 Ji Z, Wang G, Xie Z, Zhang C, Wang J. 2012. Identification and characterization of microRNA in the dairy  
443 goat (*Capra hircus*) mammary gland by Solexa deep-sequencing technology. *Molecular*  
444 *biology reports* **39**(10): 9361-9371.
- 445 Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. 2011. KEGG for integration and interpretation of  
446 large-scale molecular data sets. *Nucleic acids research*: gkr988.
- 447 Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M,  
448 Matsubara H. 2010. miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target

- 449 FSCN1 in esophageal squamous cell carcinoma. *International journal of cancer* **127**(12):  
450 2804-2814.
- 451 Kawasaki K, Okamoto M, Kurosawa T, Nakade T, Kirisawa R, Miyashou T, Komine M, Go T, Imazu S,  
452 Takeuchi N. 2005. Enzootic intranasal tumour virus infection in apparently healthy sheep in  
453 Japan. *The Veterinary Record* **157**(4): 118.
- 454 Kincaid RP, Sullivan CS. 2012. Virus-encoded microRNAs: an overview and a look to the future. *PLoS*  
455 *Pathog* **8**(12): e1003018.
- 456 Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO,  
457 Landthaler M. 2007. A mammalian microRNA expression atlas based on small RNA library  
458 sequencing. *Cell* **129**(7): 1401-1414.
- 459 Langmead B, Trapnell C, Pop M, Salzberg SL. 2009. Ultrafast and memory-efficient alignment of short  
460 DNA sequences to the human genome. *Genome Biol* **10**(3): R25.
- 461 Lewis BP, Shih I-h, Jones-Rhoades MW, Bartel DP, Burge CB. 2003. Prediction of mammalian microRNA  
462 targets. *Cell* **115**(7): 787-798.
- 463 Lin MV, King LY, Chung RT. 2015. Hepatitis C virus-associated cancer. *Annual Review of Pathology:*  
464 *Mechanisms of Disease* **10**: 345-370.
- 465 Livak KJ, Schmittgen TD. 2001. Analysis of Relative Gene Expression Data Using Real-Time Quantitative  
466 PCR and the  $2^{-\Delta\Delta CT}$  Method. *methods* **25**(4): 402-408.
- 467 Martínez-Gac L, Marqués M, García Z, Campanero MR, Carrera AC. 2004. Control of cyclin G2 mRNA  
468 expression by forkhead transcription factors: novel mechanism for cell cycle control by  
469 phosphoinositide 3-kinase and forkhead. *Molecular and cellular biology* **24**(5): 2181-2189.
- 470 Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger  
471 J. 1993. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain  
472 of the GRB-2 adaptor protein. *Cell* **75**(1): 175-185.
- 473 Pfeffer S, Zavolan M, Grässer FA, Chien M, Russo JJ, Ju J, John B, Enright AJ, Marks D, Sander C. 2004.  
474 Identification of virus-encoded microRNAs. *Science* **304**(5671): 734-736.
- 475 Rings D, Rojko J. 1985. Naturally occurring nasal obstructions in 11 sheep. *The Cornell veterinarian*  
476 **75**(2): 269-276.
- 477 Roy S, Jørgensen HG, Roy P, Abed El Baky M, Melo JV, Strathdee G, Holyoake TL, Bartholomew C. 2012.  
478 BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. *British*  
479 *journal of haematology* **157**(4): 446-456.
- 480 Ruby JG, Stark A, Johnston WK, Kellis M, Bartel DP, Lai EC. 2007. Evolution, biogenesis, expression, and  
481 target predictions of a substantially expanded set of Drosophila microRNAs. *Genome research*  
482 **17**(12): 1850-1864.
- 483 Schmidt M, de Mattos SF, van der Horst A, Klomp maker R, Kops GJL, Lam EW-F, Burgering BM,  
484 Medema RH. 2002. Cell cycle inhibition by FoxO forkhead transcription factors involves  
485 downregulation of cyclin D. *Molecular and cellular biology* **22**(22): 7842-7852.
- 486 Sengupta S, den Boon JA, Chen I-H, Newton MA, Stanhope SA, Cheng Y-J, Chen C-J, Hildesheim A,  
487 Sugden B, Ahlquist P. 2008. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas,  
488 up-regulating mRNAs encoding extracellular matrix proteins. *Proceedings of the National*  
489 *Academy of Sciences* **105**(15): 5874-5878.
- 490 Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P,

- 491 Perrotti D, Chan TO. 1997. Transformation of hematopoietic cells by BCR/ABL requires  
492 activation of a PI-3k/Akt-dependent pathway. *The EMBO journal* **16**(20): 6151-6161.
- 493 Smith DL, Burthem J, Whetton AD. 2003. Molecular pathogenesis of chronic myeloid leukaemia.  
494 *Expert reviews in molecular medicine* **5**(27): 1-27.
- 495 Vitellozzi G, Mughetti L, Palmarini M, Mandara M, Mechelli L, Sharp J, Manocchio I. 1993. Enzootic  
496 intranasal tumour of goats in Italy. *Journal of Veterinary Medicine, Series B* **40**(1-10): 459-468.
- 497 Walsh SR, Linnerth-Petrik NM, Laporte AN, Menzies PI, Foster RA, Wootton SK. 2010. Full-length  
498 genome sequence analysis of enzootic nasal tumor virus reveals an unusually high degree of  
499 genetic stability. *Virus research* **151**(1): 74-87.
- 500 Wang M, Kaufman RJ. 2014. The impact of the endoplasmic reticulum protein-folding environment on  
501 cancer development. *Nature Reviews Cancer* **14**(9): 581-597.
- 502 Wu S, Theodorescu D, Kerbel RS, Willson J, Mulder KM, Humphrey LE, Brattain MG. 1992. TGF-beta 1  
503 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as  
504 revealed by transfection of an antisense expression vector. *The Journal of cell biology* **116**(1):  
505 187-196.
- 506 Xia H, Ng SS, Jiang S, Cheung WK, Sze J, Bian X-W, Kung H-f, Lin MC. 2010. miR-200a-mediated  
507 downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell  
508 growth, migration and invasion. *Biochemical and biophysical research communications* **391**(1):  
509 535-541.
- 510 Ye L, Su X, Wu Z, Zheng X, Wang J, Zi C, Zhu G, Wu S, Bao W. 2012. Analysis of differential miRNA  
511 expression in the duodenum of Escherichia coli F18-sensitive and-resistant weaned piglets.  
512 *PLoS one* **7**(8): e43741.
- 513 Yi G, KaiYu W, QiGui Y, YingDong Y, DeFang C, JinLu H. 2010. Pathomorphologic observation of enzootic  
514 intranasal adenocarcinoma in Nanjiang yellow goats. *Chinese Journal of Veterinary Science*  
515 **30**(8): 1095-1097.
- 516 Yu H, Jun Y. 2014. Analysis of miRNAs between 70 Days Fetal and Lamb Skin. *Biotechnology* **5**: 018.
- 517 Yuan K, Lian Z, Sun B, Clayton MM, Ng IO, Fingleton MA. 2012. Role of miR-148a in hepatitis B  
518 associated hepatocellular carcinoma. *PLoS One* **7**(4): e35331.
- 519 Zhang X-D, Wang Y, Ye L-H. 2014. Hepatitis B virus X protein accelerates the development of hepatoma.  
520 *Cancer biology & medicine* **11**(3): 182-190.
- 521 Zhang X, Daucher M, Armistead D, Russell R, Kottlilil S. 2013. MicroRNA expression profiling in  
522 HCV-infected human hepatoma cells identifies potential anti-viral targets induced by  
523 interferon- $\alpha$ . *PLoS One* **8**(2): e55733.

524

525

526 **Supporting Information**

527 **Figure1-6 . Reads length distribution statistical of S1-6**

528 **Figure 7.** Base quality distribution in each cycle.

529

530 **Figure 8.** Relative expression of miRNAs in ENA and para-cancerous tissues. The *x*- and

531 *y*-axes indicate the mean TPM expression levels of the miRNAs in each tissue. The red circles

532 represent miRNAs with a fold change  $\geq 2$ ; green circles represent miRNAs with a fold change

533  $\leq 2$ ; the points on the dotted line represent miRNAs with a fold change = 2. Fold changes

534 were calculated as the mean miRNA TPM in ENA/mean miRNA TPM in para-cancerous

535 tissues.

536

537 **Figure 9.** The ten most-enriched GO categories of the differentially expressed target genes of

538 the differentially expressed miRNAs.

539 (PDF)

540

541 **Figure 10.** The ten most-enriched signaling pathways of the differentially expressed target

542 genes of the differentially expressed miRNAs.

543 (PDF)

544

545 **Figure 11.**qRT-PCR validation of the identified miRNAs using Illumina sequencing

546 technology. Real-time RT-PCR analysis of nine miRNAs in the tumour and para-carcinoma

547 tissues from 5 goats with ENA. Relative quantification was assessed using the  $2^{-\Delta\Delta Cq}$  method

548 and was normalized to *U6* and *GAPDH*.  $2^{-\Delta\Delta C_t}$  Means  $\pm$  SE relative expression levels are

549 presented. \* represents  $p < 0.05$ , \*\* represents  $p < 0.01$ .

550

551 **Table 1.** Clean reads and unique reads from the ENA and para-cancerous tissues that mapped

552 to the *Capra hircus* genome.

553

554 **Table S1.** The miRNAs expressed in samples detected by Illumina sequencing.

555 (XLSX)

556

557 **Table S2.** Blast results of all miRNAs against human miRNAs in miRBase v21.

558 (XLS)

559

560 **Table S3.** The expression of miRNAs in ENA and para-cancerous tissues.

561 (XLS)

562

563 **Table S4.** Significantly differentially expressed miRNAs in ENA.

564 (.XLSX)

565 Positive FoldChange\_Log2 indicates upregulation in ENA relative to the para-cancerous

566 tissues; a negative FoldChange\_Log2 indicates downregulation in ENA relative to the

567 para-cancerous tissues; inf indicates no expression in para-cancerous tissues; -inf indicates no

568 expression in ENA.

569



570

571 **Table S5.** Predicted target genes of the differently expressed miRNAs in ENA.

572 (XLS)

573

574 **Table S6.** Differentially expressed miRNAs and their differentially expressed target genes in

575 ENA.

576 (XLS)

577

578 **Table S7.** Node attributes of the differentially expressed miRNAs and their differentially

579 expressed target genes in ENA.

580 (XLSX)

581

582 **Table S8.** Significantly enriched gene ontology categories the differentially expressed target

583 genes of the differentially expressed miRNAs.

584 (XLS)

585

586 **Table S9.** Significantly enriched signaling pathways (m=83)of gene targets of the

587 significantly increased miRNAs in ENA.

588 (XLS)


589

590 **Table S10.** Significantly enriched signaling pathways (m=89)of gene targets of the


591 significantly reduced miRNAs in ENA.

592 (XLS)


593




**Fig.1** Reads length distribution statistical of S1




**Fig .2 Reads length distribution statistical of S2**




**Fig.3** Reads length distribution statistical of S3



**Fig.4** Reads length distribution statistical of S4




**Fig .5** Reads length distribution statistical of S5




**Fig .6** Reads length distribution statistical of S6







**Fig. 7** Base quality distribution in each cycle




**Fig. 8 Relative expression of miRNAs in ENA and para-cancerous tissues.** The  $x$ - and  $y$ -axes indicate the mean TPM expression levels of the miRNAs in each tissue. The red circles represent miRNAs with a fold change  $\geq 2$ ; green circles represent miRNAs with a fold change  $\leq 2$ ; the points on the dotted line represent miRNAs with a fold change = 2. Fold changes were calculated as the mean miRNA TPM in ENA/mean miRNA TPM in para-cancerous tissues.





**Figure 11** miRNAs expression patterns in nasal tissue



**Fig. 11 qRT-PCR validation of the identified miRNAs using Illumina sequencing**

**technology.** Real-time RT-PCR analysis of nine miRNAs in the tumour and para-carcinoma tissues from 5 goats with ENA. Relative quantification was assessed using the  $2^{-\Delta \Delta Cq}$  method and was normalized to *U6* and *GAPDH*.  $2^{-\Delta \Delta Cq}$  Means  $\pm$ SE relative expression levels are presented. \* represents  $p < 0.05$ , \*\* represents  $p < 0.01$ .

**Table 1**

**Table 1 The results of clean reads and unique reads mapped to the Capra Hircus genome in cancer and control groups.**

Samples	Clean reads	Total aligned reads	Total aligned reads(%)	Total unaligned reads	Total unaligned reads(%)	Unique reads	Unique aligned reads	Unique aligned reads(%)	Unique unaligned reads	Unique unaligned reads(%)
S1	8009909	7174638	89.57	835271	10.43	335710	239081	71.22	96629	28.78
S2	9883394	8614567	87.16	1268827	12.84	236291	149260	63.17	87031	36.83
S3	5129861	4573796	89.16	556065	10.84	204228	127183	62.28	77045	37.72
S4	4847129	4108137	84.75	738992	15.25	203603	117200	57.56	86403	42.44
S5	5269861	4598556	87.26	671305	12.74	231658	154306	66.61	77352	33.39
S6	5627178	4846400	86.12	780778	13.88	225210	143168	63.57	82042	36.43